Gain critical insights with Haystack MRD
-
Exceptional sensitivity
-
Tumor-informed
-
Personalized
-
Track 50 variants
-
Baseline and Monitoring
Purpose-built
A personalized approach to cancer care
Haystack MRD was developed by researchers who understand the importance of providing accurate data for confident treatment decisions. Our ctDNA testing uncovers the insights you need to make confident decisions compared to traditional methods for cancer treatment when answering patients’ most pressing postsurgery questions:
High-precision
Exceptional sensitivity to enhance your expertise
Haystack MRD’s technology enables ultrasensitive ctDNA testing with the ability to detect 95% of cases at 0.0006% tumor fraction. With such a low limit of detection, you can uncover the insights you need to help you make earlier and more confident treatment decisions.
This graphic is a theoretical representation only
-
Hover over the timepoints in the figure below to discover how Haystack MRD can provide insights into your treatment decisions.Important
Neoadjuvant therapy
Exceptional sensitivity and specificity for informed neoadjuvant therapy decision-making
Adjuvant therapy
Follow patient’s response to adjuvant therapy to greater depths and with better sensitivity than traditional methods
Second and third line therapy
Limit of detection of 0.0006% means that patients who recur may be identified earlier than with traditional methods
Second and third line therapy
Limit of detection of 0.0006% means that patients who recur may be identified earlier than with traditional methods
Foundational Clinical utility
